Suppr超能文献

血压控制、高血压表型与蛋白尿:巴塞尔产后高血压综合登记研究的结果

Blood pressure control, hypertension phenotypes, and albuminuria: outcomes of the comprehensive Basel Postpartum Hypertension Registry.

作者信息

Hotz Leana N, Burkard Thilo, Rana Alessandro, Wenker Celine A, Jalanthiran Subeedhja, Piattini Leana, Strobel Noémie, Vorster Viviane, Menzinger Zoë G, Eichler Sophia, Schumacher Christina, Mayr Michael, Dickenmann Michael, Hoesli Irene, Lapaire Olav, Mosimann Beatrice, Vischer Annina S, Socrates Thenral

机构信息

Medical Outpatient Department and Hypertension Centre, ESH Hypertension Centre of Excellence, University Hospital Basel, Basel, Switzerland.

Department of Cardiology, University Hospital Basel, Basel, Switzerland.

出版信息

Hypertens Res. 2025 Apr 25. doi: 10.1038/s41440-025-02191-2.

Abstract

Postpartum hypertension (PPHT) affects 20% of pregnancies and is strongly correlated to cardiovascular and kidney disease. Most outcome data stems from preeclampsia (PE) neglecting other hypertensive disorders of pregnancy (HDP). This analysis aimed to investigate blood pressure (BP) control, BP phenotypes, therapeutic intensity scores (TIS), and albuminuria across the spectrum of PPHT in the short-medium term.This analysis prospectively followed 370 cases of PPHT. Automated office BP measurements (AOBPM), 24-hour ambulatory BP measurements (24ABPM), TIS and Kidney Disease Improving Global Outcomes (KDIGO) > A2 levels of albumin to creatinine ratio (ACR) were measured at 3 (V3) and 12 (V12) months postpartum. Outcomes were percentage of participants with non-hypertensive AOBPM and awake 24ABPM, whitecoat, and masked hypertension, and an A2 ACR at V3 and V12. The Basel-PPHT cohort consisted of 11.9% (n = 44) chronic hypertension, 31.9% (n = 118) gestational hypertension, 55.4% (n = 205) PE, eclampsia or HELLP, and 18.4% (n = 68) de novo PPHT. Antihypertensive medication was prescribed at baseline, V3 and V12 in 85.4% (n = 316), 19.2% (n = 46), and 20% (n = 21). At V12, 9.3% (n = 5) with PE, eclampsia, and HELLP vs 31.4% (n = 16) of the remaining cohort required antihypertensive medication, p = 0.005. Non-hypertensive BP without medication was seen at V3 and V12 in 47.9% (n = 103) and 62.4% (n = 63), respectively. Albuminuria at baseline, V3 and V12 was 84.9% (n = 124), 29.9% (n = 63), and 16.9% (n = 14) respectively. The Basel-PPHT registry identified undertreatment and persistent albuminuria, despite structured management. Importantly, those without preeclampsia also required stricter controls. Therefore, rigorous follow-ups are crucial for enhancing cardiovascular and renal outcomes in this population.

摘要

产后高血压(PPHT)影响20%的妊娠,且与心血管疾病和肾脏疾病密切相关。大多数结局数据源于先兆子痫(PE),而忽略了其他妊娠高血压疾病(HDP)。本分析旨在研究短期至中期PPHT范围内的血压(BP)控制、BP表型、治疗强度评分(TIS)和蛋白尿情况。本分析前瞻性地随访了370例PPHT病例。在产后3个月(V3)和12个月(V12)时测量自动诊室血压测量值(AOBPM)、24小时动态血压测量值(24ABPM)、TIS以及改善全球肾脏病预后组织(KDIGO)定义的白蛋白与肌酐比值(ACR)>A2水平的蛋白尿。结局指标为V3和V12时非高血压AOBPM和清醒状态下24ABPM、白大衣高血压、隐匿性高血压以及A2 ACR的参与者百分比。巴塞尔PPHT队列包括11.9%(n = 44)的慢性高血压、31.9%(n = 118)的妊娠期高血压、55.4%(n = 205)的PE、子痫或HELLP以及18.4%(n = 68)的新发PPHT。在基线、V3和V12时分别有85.4%(n = 316)、19.2%(n = 46)和20%(n = 21)的患者使用了降压药物。在V12时,患有PE、子痫和HELLP的患者中有9.3%(n = 5)需要降压药物治疗,而其余队列中有31.4%(n = 16)需要,p = 0.005。V3和V12时分别有47.9%(n = 103)和62.4%(n = 63)的患者在未使用药物的情况下血压正常。基线、V3和V12时的蛋白尿发生率分别为84.9%(n = 124)、29.9%(n = 63)和16.9%(n = 14)。巴塞尔PPHT登记处发现,尽管进行了结构化管理,但仍存在治疗不足和持续性蛋白尿的情况。重要的是,那些没有先兆子痫的患者也需要更严格的控制。因此,严格的随访对于改善该人群的心血管和肾脏结局至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验